Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography–tandem mass spectrometry
Authors:
- R.W. SparidansRSR.W. Sparidans
- A.D.R. HuitemaAHA.D.R. Huitema
- J.H.M. SchellensJSJ.H.M. Schellens
- J.H. BeijnenJBJ.H. Beijnen
- 1 June 2006
- journal article
- research article
- Published by Elsevier in Journal of Chromatography B
- Vol. 837 (1-2) , 49-58
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- T‐1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide‐Containing Treatment RegimenThe Journal of Infectious Diseases, 2005
- The Appealing Story of HIV Entry InhibitorsDrugs, 2005
- Pharmacokinetics, Pharmacodynamics and Drug Interaction Potential of EnfuvirtideClinical Pharmacokinetics, 2005
- Peptide inhibitors of virus—cell fusion: enfuvirtide as a case study in clinical discovery and developmentThe Lancet Infectious Diseases, 2004
- Enfuvirtide: first fusion inhibitor for treatment of HIV infectionAmerican Journal of Health-System Pharmacy, 2004
- Short‐Term Safety and Antiretroviral Activity of T‐1249, a Second‐Generation Fusion Inhibitor of HIVThe Journal of Infectious Diseases, 2004
- Enfuvirtide, a New Fusion Inhibitor for Therapy of Human Immunodeficiency Virus InfectionPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2004
- Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patientsJournal of Clinical Virology, 2003
- EnfuvirtideDrugs, 2003
- Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patientswith human immunodeficiency virus: Inverse Gaussian density absorption and 2‐compartment disposition*Clinical Pharmacology & Therapeutics, 2002